查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600269

結核病檢測市場：按檢測項目、適應症、檢測地點和最終用戶分類 - 全球預測 2025-2030

Tuberculosis Testing Market by Test (Culture-Based Tests, Interferon-Gamma Release Assays, Mantoux Tuberculin Skin Test), Indication (Active TB Infection, Latent TB Infection), Testing Location, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年結核病檢測市場價值為22.5億美元，預計到2024年將達到23.8億美元，複合年成長率為5.88%，到2030年將達到33.6億美元。

結核病檢測市場包括用於檢測結核病感染的各種診斷測試，例如皮膚測試、血液檢查、顯微鏡檢查、核酸測試和基於培養的測試。這些檢測對於識別活動性結核病病例和潛伏性結核病感染至關重要，有助於限制這種傳染病的傳播。結核病檢測的必要性在於其在流行區域和非流行區的應用，以遏制傳播並提供有針對性的治療。結核病檢測在醫院、診所和診斷實驗室等醫療機構中至關重要，有助於衛生署和政府改善公共衛生的努力。該市場的促進因素包括發病率的增加、對早期準確診斷的需求不斷成長以及測試準確性和速度的進步。該領域最新的潛在商機之一來自數位健康技術和人工智慧測試解釋的整合，這可能會導致更快的診斷和改進的患者管理。市場成長受到政府努力根除結核病、提高意識和篩檢計畫以及增加研發資金等因素的影響。限制包括特別先進的分子測試的高成本、資源匱乏環境中的基礎設施挑戰以及對熟練人員的需求。挑戰包括結核病感染的隱藏性，這使得及時診斷和公共衛生應對變得複雜。最佳的創新領域是開發更容易獲得且更具成本效益的就地檢驗，這些測試可以在偏遠和服務不足的地區進行。這包括快速檢測套組和移動測試裝置等。疫苗開發研究也是創新的沃土。該市場正在適應公共衛生機構和私人公司之間日益加強的夥伴關係關係，以加強檢測基礎設施和推廣計劃，使其成為一個充滿機會和挑戰的充滿活力的領域。

主要市場統計
基準年[2023] 22.5億美元
預測年份 [2024] 23.8億美元
預測年份 [2030] 33.6億美元
複合年成長率（%） 5.88%

市場動態：揭示快速發展的結核病檢測市場的關鍵市場洞察

供需的動態交互作用正在改變結核病檢測市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球結核病患率上升
    • 政府和監管機構提高對結核病的認知和控制計劃
    • 照護現場高機率結核病檢測
  • 市場限制因素
    • 高階結核病檢測成本高昂
  • 市場機會
    • 不斷發展診斷技術以實現更快的診斷
    • 增加配備先進設備的結核病診斷中心數量
  • 市場挑戰
    • 擅長管理和解釋結核病檢測的醫療保健專業人員

波特五力：開拓結核病檢測市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解結核病檢測市場的外部影響

外部宏觀環境因素在塑造結核病檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解結核病檢測市場的競爭格局

對結核病檢測市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣結核病檢測市場供應商的績效評估

FPNV定位矩陣是評估結核病檢測市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃結核病檢測市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，結核病檢測市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告提供了涵蓋關鍵重點領域的市場全面分析：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地的結核病發病率正在上升
      • 政府和監管機構擴大結核病認知和控制計劃
      • 照護現場高機率結核病檢測
    • 抑制因素
      • 高階結核病檢測高成本
    • 機會
      • 不斷發展診斷技術以實現更快的診斷
      • 增加配備先進設備的結核病診斷中心
    • 任務
      • 熟悉執行和解釋結核病檢測的熟練醫療保健專業人員
  • 市場區隔分析
    • 檢驗：非侵入性和有效性正在增加 IGRA 在診斷潛伏性結核感染的使用
    • 最終用戶：透過政府和公共衛生機構輕鬆進行結核病檢測，以減少結核病的傳播並實現公共衛生目標。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 結核病檢測市場（依檢測）

  • 基於文化的測試
  • 干擾素-γ釋放測定
  • Mantot結核菌素皮膚試
  • 核酸增幅檢查
  • 塗片顯微鏡檢查

第7章 結核病檢測市場（依適應症）

  • 活動性結核感染疾病
  • 潛伏性結核感染

第8章依檢測地點分類的結核病檢測市場

  • 實驗室測試
  • 就地檢驗

第9章結核病檢測市場：依最終用戶分類

  • 診斷實驗室
  • 政府和公共衛生機構
  • 醫院
  • 研究/學術機構

第10章美洲結核病檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太結核病檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲結核病檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭場景分析
    • Revvity 推出先進的結核病檢測自動化技術，提高效率和準確性
    • MedGenome 與 Darshan GIVA 基金會合作，透過全基因組定序增強結核病診斷
    • VinBrain 與越南國家結核病篩檢舉措合作根除結核病
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bruker Corporation
  • Cepheid by Danaher Corporation
  • Elisabeth Pharmacon, spol. s ro
  • ELITech Group SAS
  • F. Hoffmann-La Roche AG
  • Fujifilm Holdings Corporation
  • Hologic Corporation
  • Lionex Diagnostics & Therapeutics GmbH
  • OSANG HEALTHCARE CO., LTD
  • PerkinElmer, Inc.
  • SD Biosensor, INC.
  • Siemens AG
  • Thermo Fisher Scientific, Inc.
  • Trivitron Healthcare Private Limited
  • Tulip Diagnostics（P）Ltd
  • Turklab AS
Product Code: MRR-03252A5F927A

The Tuberculosis Testing Market was valued at USD 2.25 billion in 2023, expected to reach USD 2.38 billion in 2024, and is projected to grow at a CAGR of 5.88%, to USD 3.36 billion by 2030.

The scope of the Tuberculosis (TB) Testing market encompasses various diagnostic tests used to detect TB infections, including skin tests, blood tests, microscopy, nucleic acid tests, and culture-based tests. These tests are crucial in identifying active TB cases and latent TB infections, which aids in controlling the spread of this contagious disease. The necessity of TB testing lies in its application in both endemic and non-endemic regions to curb transmission and provide targeted treatment. They are essential in healthcare settings such as hospitals, clinics, and diagnostic laboratories, serving health departments and governments aiming for public health advancement. The market is driven by increasing incidence rates, a rising need for early and precise diagnostics, and advancements in test accuracy and speed. One of the latest potential opportunities within this sector arises from the integration of digital health technologies and AI for test interpretation, which can lead to quicker diagnosis and improved patient management. Market growth is influenced by factors such as government initiatives for TB eradication, rising awareness and screening programs, and increasing funding for R&D. Limitations include high costs, especially for advanced molecular tests, infrastructural challenges in low-resource settings, and the requirement for skilled personnel. A challenging factor is the latent nature of TB infections, which complicates timely diagnosis and public health responses. The best areas for innovation touch upon developing more accessible, cost-effective point-of-care tests that can be implemented in remote or underserved areas. This could include simplified test kits or mobile testing units. Research into vaccine development also represents a fertile ground for innovation. The market is adapting with an increase in partnerships between public health bodies and private enterprises to enhance testing infrastructure and outreach programs, making it a dynamic field ripe with both opportunities and challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 2.25 billion
Estimated Year [2024] USD 2.38 billion
Forecast Year [2030] USD 3.36 billion
CAGR (%) 5.88%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Tuberculosis Testing Market

The Tuberculosis Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rise in the prevalence of tuberculosis worldwide
    • Growing tuberculosis awareness and control programs by government and regulatory authorities
    • High potential of point-of-care tuberculosis testing
  • Market Restraints
    • High cost of advanced tuberculosis testings
  • Market Opportunities
    • Ongoing developments in diagnostic technologies that enable faster diagnosis
    • Increasing number of tuberculosis diagnostic centers with advanced facilities
  • Market Challenges
    • Skilled healthcare professionals proficient in administering and interpreting TB tests

Porter's Five Forces: A Strategic Tool for Navigating the Tuberculosis Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Tuberculosis Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Tuberculosis Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Tuberculosis Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Tuberculosis Testing Market

A detailed market share analysis in the Tuberculosis Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Tuberculosis Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Tuberculosis Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Tuberculosis Testing Market

A strategic analysis of the Tuberculosis Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Tuberculosis Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc., bioMerieux SA, Bruker Corporation, Cepheid by Danaher Corporation, Elisabeth Pharmacon, spol. s r.o., ELITech Group SAS, F. Hoffmann-La Roche AG, Fujifilm Holdings Corporation, Hologic Corporation, Lionex Diagnostics & Therapeutics GmbH, OSANG HEALTHCARE CO., LTD, PerkinElmer, Inc., SD Biosensor, INC., Siemens AG, Thermo Fisher Scientific, Inc., Trivitron Healthcare Private Limited, Tulip Diagnostics (P) Ltd, and Turklab A.S..

Market Segmentation & Coverage

This research report categorizes the Tuberculosis Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Test, market is studied across Culture-Based Tests, Interferon-Gamma Release Assays, Mantoux Tuberculin Skin Test, Nucleic Acid Amplification Tests, and Smear Microscopy.
  • Based on Indication, market is studied across Active TB Infection and Latent TB Infection.
  • Based on Testing Location, market is studied across In-laboratory Testing and Point-of-Care Testing.
  • Based on End User, market is studied across Diagnostic Laboratories, Government & Public Health Organizations, Hospital, and Research & Academic Institutions.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rise in the prevalence of tuberculosis worldwide
      • 5.1.1.2. Growing tuberculosis awareness and control programs by government and regulatory authorities
      • 5.1.1.3. High potential of point-of-care tuberculosis testing
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of advanced tuberculosis testings
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing developments in diagnostic technologies that enable faster diagnosis
      • 5.1.3.2. Increasing number of tuberculosis diagnostic centers with advanced facilities
    • 5.1.4. Challenges
      • 5.1.4.1. Skilled healthcare professionals proficient in administering and interpreting TB tests
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test: Growing usage of IGRA in diagnosing latent TB infection due to their non-invasive nature and effectiveness
    • 5.2.2. End User: High accessibility to tuberculosis testing through government and public health organizations to curb the spread of TB and achieve public health goals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Tuberculosis Testing Market, by Test

  • 6.1. Introduction
  • 6.2. Culture-Based Tests
  • 6.3. Interferon-Gamma Release Assays
  • 6.4. Mantoux Tuberculin Skin Test
  • 6.5. Nucleic Acid Amplification Tests
  • 6.6. Smear Microscopy

7. Tuberculosis Testing Market, by Indication

  • 7.1. Introduction
  • 7.2. Active TB Infection
  • 7.3. Latent TB Infection

8. Tuberculosis Testing Market, by Testing Location

  • 8.1. Introduction
  • 8.2. In-laboratory Testing
  • 8.3. Point-of-Care Testing

9. Tuberculosis Testing Market, by End User

  • 9.1. Introduction
  • 9.2. Diagnostic Laboratories
  • 9.3. Government & Public Health Organizations
  • 9.4. Hospital
  • 9.5. Research & Academic Institutions

10. Americas Tuberculosis Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Tuberculosis Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Tuberculosis Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Revvity Introduces Advanced Automation for Tuberculosis Testing, Enhancing Efficiency and Accuracy
    • 13.3.2. MedGenome Collaborates with Darshan GIVA Foundation to Enhance TB Diagnosis through Whole Genome Sequencing
    • 13.3.3. VinBrain Partners with Vietnam's National TB Screening Initiative to Combat Tuberculosis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Becton, Dickinson, and Company
  • 3. Bio-Rad Laboratories, Inc.
  • 4. bioMerieux SA
  • 5. Bruker Corporation
  • 6. Cepheid by Danaher Corporation
  • 7. Elisabeth Pharmacon, spol. s r.o.
  • 8. ELITech Group SAS
  • 9. F. Hoffmann-La Roche AG
  • 10. Fujifilm Holdings Corporation
  • 11. Hologic Corporation
  • 12. Lionex Diagnostics & Therapeutics GmbH
  • 13. OSANG HEALTHCARE CO., LTD
  • 14. PerkinElmer, Inc.
  • 15. SD Biosensor, INC.
  • 16. Siemens AG
  • 17. Thermo Fisher Scientific, Inc.
  • 18. Trivitron Healthcare Private Limited
  • 19. Tulip Diagnostics (P) Ltd
  • 20. Turklab A.S.

LIST OF FIGURES

  • FIGURE 1. TUBERCULOSIS TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. TUBERCULOSIS TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TUBERCULOSIS TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE-BASED TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INTERFERON-GAMMA RELEASE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MANTOUX TUBERCULIN SKIN TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SMEAR MICROSCOPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TB INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TB INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IN-LABORATORY TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY POINT-OF-CARE TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GOVERNMENT & PUBLIC HEALTH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TEST, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TESTING LOCATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 193. TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2023